Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Exact Sciences Corp.
Nieuws
Exact Sciences Corp.
EXAS
NAS
: EXAS
| ISIN: US30063P1057
14/02/2025
49,31 USD
(-2,53%)
(-2,53%)
14/02/2025
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
31 juli 2024 ·
TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology
· Persbericht
7 januari 2024 ·
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
· Persbericht
2 januari 2024 ·
Exact Sciences to participate in J.P. Morgan Healthcare Conference
· Persbericht
7 december 2023 ·
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings
· Persbericht
1 november 2023 ·
Exact Sciences Announces Third-Quarter 2023 Results
· Persbericht
1 november 2023 ·
Exact Sciences to participate in November investor conferences
· Persbericht
22 oktober 2023 ·
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection
· Persbericht
21 oktober 2023 ·
Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress
· Persbericht
9 oktober 2023 ·
Exact Sciences schedules third quarter 2023 earnings call
· Persbericht
9 oktober 2023 ·
Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
· Persbericht
1 september 2023 ·
Exact Sciences to participate in September investor conference
· Persbericht
30 augustus 2023 ·
Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical Trials
· Persbericht
21 augustus 2023 ·
Not a Wall, But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings
· Persbericht
1 augustus 2023 ·
Exact Sciences Announces Second-Quarter 2023 Results
· Persbericht
10 juli 2023 ·
Exact Sciences schedules second quarter 2023 earnings call
· Persbericht
21 juni 2023 ·
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
· Persbericht
20 juni 2023 ·
Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening
· Persbericht
1 juni 2023 ·
Exact Sciences Earns 2023 Great Place To Work® Certification™
· Persbericht
1 juni 2023 ·
Exact Sciences to participate in June investor conferences
· Persbericht
26 mei 2023 ·
Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe